Sudden Severe SNHL in a 27-Year-Old - Management and Prognosis

Audiogram Interpretation

• Right ear: Near-normal (PTA ~11.6 dB HL, O symbols tracking close to 0 dB line)
• Left ear: Severe SNHL - X markers showing thresholds at 40-80+ dB HL, worsening at high frequencies (downsloping/flat-to-sloping configuration)
• Weber: Lateralizes to the RIGHT (the better ear) - confirms left-sided loss
• Rinne: Positive bilaterally - confirms sensorineural (not conductive) nature
• Provisional diagnosis (audiologist): Severe SNHL within the left ear

Immediate Management (Treat as Otologic Emergency)

Step 1: Urgent ENT Referral (already recommended on the form)

Step 2: Confirm Diagnosis and Exclude Secondary Causes

• MRI with gadolinium (IAM/posterior fossa) - to exclude retrocochlear pathology (vestibular schwannoma), mandatory per AAO-HNS guidelines. If MRI unavailable: auditory brainstem response (ABR).
• Routine labs are NOT recommended by guidelines, but reasonable to check: FBC, ESR, CRP, fasting glucose, lipids, TFT, coagulation screen, antiphospholipid antibodies (especially in a 27-year-old)
• In young patients: consider ANA, ANCA, anti-Ro/La if autoimmune suspected

Step 3: Treatment

• Protocol: Full dose for 4 days, then reduce by 10 mg every 2 days
• Add proton pump inhibitor (omeprazole 20 mg OD) to protect gastric mucosa
• Advise: take in the morning as a single dose
• At 27 years old with no contraindications, systemic steroids are well-tolerated

Per Cummings Otolaryngology: "Oral steroid therapy within the first 2 weeks has shown recovery rates up to 80%" (Cummings Otolaryngology, p. 3035)

• IT Dexamethasone (4-24 mg/mL) or IT Methylprednisolone (62.5 mg/mL), 0.3-0.5 mL per injection
• Recommended within 2-6 weeks of symptom onset (AAO-HNS KAS 10 - Recommended)
• Can be used as primary therapy if systemic steroids are contraindicated (e.g., diabetes, peptic ulcer, psychiatric illness)

• Can be offered in combination with steroids within 2 weeks of onset (initial therapy)
• Or as salvage within 1 month of onset
• Most effective in moderate-to-severe losses (≥60 dB) - which applies to this patient
• 2026 meta-analysis (PMID: 40747804) confirms benefit in SSNHL, particularly in severe cases

• Antivirals (acyclovir/valacyclovir) - not routinely recommended
• Vasodilators, rheologic agents (carbogen, dextran)
• Thrombolytics
• Antioxidants (evidence insufficient)

Step 4: Monitoring

• Repeat audiogram at 2 weeks (end of steroid course)
• If incomplete recovery: offer IT steroids as salvage
• Follow-up audiometry at 6 months (per AAO-HNS)
• If recovery is incomplete at 3 months: discuss hearing rehabilitation options

Prognosis for This Patient

• Young age (27 years) - age <40 carries better prognosis than older adults
• Unilateral loss - bilateral SSNHL has significantly worse prognosis
• Absence of vertigo (not mentioned - confirm clinically; if absent, this is favorable)

• Severe loss - the audiogram shows marked elevation in left ear thresholds (downsloping into the severe range). The more severe the loss, the worse the prognosis.
• Downsloping/flat configuration - upsloping or mid-frequency losses recover better than downsloping
• Reduced speech discrimination (if confirmed on speech audiometry) - carries poor prognosis

"Without treatment, 30-65% of patients experience complete or partial spontaneous recovery. Four variables affect prognosis: (1) severity of loss, (2) audiogram shape, (3) presence of vertigo, and (4) age." - Cummings Otolaryngology, p. 2939

"Most recovery occurs within the first 2 weeks after onset... Those who have not meaningfully recovered by 3 months are unlikely to do so." - Cummings Otolaryngology, p. 2939

• Mild losses: ~80% recovery rate
• Moderate losses: ~50-60% recovery
• Severe losses (this patient): recovery rates lower, approximately 30-50% with aggressive treatment; significant residual hearing loss is common
• Profound losses: <20% meaningful recovery

Rehabilitation if Persistent Loss

• Hearing aid (conventional or BAHA if severe enough)
• Cochlear implant - patients with SSNHL resulting in single-sided deafness are now recognized candidates for unilateral CI
• Tinnitus management (sound therapy, CBT if present)
• Audiologic rehabilitation

Summary Action Plan

1. Urgent ENT review (already recommended - within days, not weeks)
2. Start oral prednisone 60 mg/day immediately (do not wait for MRI)
3. MRI with gadolinium (IAM) - to exclude acoustic neuroma / retrocochlear pathology
4. Repeat audiogram in 2 weeks
5. If no response: IT dexamethasone as salvage therapy (within 2-6 weeks of onset)
6. Consider HBOT referral if available, especially given severe loss
7. Counsel on prognosis: guarded but treatable - young age is the key positive factor

Caroverine in This Case of Sudden Severe SNHL

What Is Caroverine?

Mechanism of Action - Why It Is Relevant to SNHL

1. Normal cochlear neurotransmission: Inner hair cells (IHCs) release glutamate onto spiral ganglion neuron (SGN) afferents via AMPA and NMDA receptors.
2. In sudden/ischemic SNHL: Cochlear ischemia, noise trauma, or viral insult causes massive glutamate release → over-activation of AMPA and NMDA receptors → excessive Ca²⁺ influx into SGNs → excitotoxic injury to the dendrites and synapses of the auditory nerve.
3. Caroverine's dual action:
   • Potent AMPA receptor antagonist (primary mechanism)
   • Weak NMDA receptor antagonist (secondary)
   • Blocks glutamate-induced firing of afferent fibers of cochlear inner hair cells
   • Reduces mitochondrial free radical overproduction → protects IHC-SGN synapses

"Glutamatergic neurotoxicity is characterized by a mitochondrial overproduction of free oxygen radicals damaging lipid membranes and DNA structures of the postsynaptic neuron followed by the clinical symptoms of hearing loss and tinnitus." - Ehrenberger K, 2002 (PMID: 11885656)

Clinical Evidence in Sudden SNHL

• Enrolled patients with strictly unilateral severe sudden SNHL >70 dB HL (similar to this patient)
• Excluded spontaneous-recovery confounders by specifically targeting losses >70 dB (generally unfavorable prognosis)
• Treatment: IV caroverine 160 mg in 250 mL 0.9% NaCl, twice daily, infused at 2 mL/min within the first 2 weeks of onset
• Results: "Complete recovery for low and middle frequencies and good recovery for high frequencies" - a "highly significant therapeutic benefit in contrast to rheological and vasoactive drugs"

• Placebo-controlled blind study (n=60)
• IV caroverine up to 160 mg
• 63.3% of treated patients showed significant tinnitus reduction vs. 0% in placebo
• Relevant because tinnitus and acute SNHL share the same excitotoxic cochlear mechanism

• Guinea pig study: IV administration achieves therapeutic perilymph concentrations
• Round window membrane local application achieves much higher perilymph levels with lower systemic exposure - potentially safer and more efficacious route
• Effects on hearing are transient and fully reversible

Applicability to This 27-Year-Old

Dosing Protocol (Ehrenberger/Vienna Protocol)

• Route: IV infusion (NOT oral - poor cochlear bioavailability orally)
• Dose: 160 mg caroverine hydrochloride in 250 mL 0.9% NaCl
• Rate: 2 mL/min (slow infusion over ~2 hours)
• Frequency: Twice daily
• Duration: Typically 5-10 days (within first 2 weeks of onset)
• Timing: Must be administered within 2 weeks of onset for any benefit - identical to the steroid window

Position in the Treatment Algorithm for This Patient

FIRST LINE (evidence-based, guideline-supported):
  ├── Oral prednisone 1 mg/kg/day × 10-14 days  ← do this regardless
  └── +/- Intratympanic dexamethasone (if severe, or primary IT therapy)

ADJUNCT (where available, mechanistically sound):
  └── IV Caroverine 160 mg BD × 5-10 days  ← add if available in your country

SALVAGE (if no response at 2 weeks):
  ├── IT steroid injections
  └── Hyperbaric oxygen therapy

• Steroids: reduce endolymphatic/cochlear inflammation, vascular permeability, immune-mediated damage
• Caroverine: blocks excitotoxic glutamate cascade at the IHC-SGN synapse

Limitations and Honest Assessment

Bottom Line for This Case

• If you are practicing in Austria/Switzerland where caroverine is registered: it is reasonable to add IV caroverine to the standard corticosteroid regimen within the first 2 weeks, given the severe loss and favorable risk profile in a young patient.
• If practicing elsewhere (most of the world): caroverine is unavailable. Prioritize steroids + IT salvage + HBOT per AAO-HNS guidelines. Memantine is a partial structural alternative but targets NMDA only, not AMPA.
• The silence in recent literature (no new trials, no guideline adoption) means this therapy has not been validated at scale. Inform the patient accordingly.